Shares of Incyte Corp. INCY rose 1.39% to $62.78 Monday, on what proved to be an all-around positive trading session for the ...

These eight projects took top marks in the three office subcategories for this year's Best Real Estate Deals awards program.

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...

The stock's fall snapped a four-day winning streak.

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Fintel reports that on March 18, 2025, Guggenheim downgraded their outlook for Incyte (NasdaqGS:INCY) from Buy to Neutral.

Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...

Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and ...